Sapacitabine: Phase II started

Cyclacel began a U.S. Phase II trial to evaluate 200, 300 and 400 mg oral sapacitabine in 60 patients. The company licensed exclusive rights to sapacitabine from Daiichi Sankyo (see BioCentury, Dec. 8...